JP2022505597A5 - - Google Patents

Info

Publication number
JP2022505597A5
JP2022505597A5 JP2021521995A JP2021521995A JP2022505597A5 JP 2022505597 A5 JP2022505597 A5 JP 2022505597A5 JP 2021521995 A JP2021521995 A JP 2021521995A JP 2021521995 A JP2021521995 A JP 2021521995A JP 2022505597 A5 JP2022505597 A5 JP 2022505597A5
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
salt according
fluorine atoms
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021521995A
Other languages
English (en)
Japanese (ja)
Other versions
JP7500555B2 (ja
JP2022505597A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059004 external-priority patent/WO2020084480A1/en
Publication of JP2022505597A publication Critical patent/JP2022505597A/ja
Publication of JP2022505597A5 publication Critical patent/JP2022505597A5/ja
Application granted granted Critical
Publication of JP7500555B2 publication Critical patent/JP7500555B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021521995A 2018-10-25 2019-10-22 ヒト免疫不全ウイルス複製の阻害剤 Active JP7500555B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862750395P 2018-10-25 2018-10-25
US62/750,395 2018-10-25
PCT/IB2019/059004 WO2020084480A1 (en) 2018-10-25 2019-10-22 Inhibitors of human immunodeficiency virus replication

Publications (3)

Publication Number Publication Date
JP2022505597A JP2022505597A (ja) 2022-01-14
JP2022505597A5 true JP2022505597A5 (cg-RX-API-DMAC7.html) 2022-10-11
JP7500555B2 JP7500555B2 (ja) 2024-06-17

Family

ID=68344929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521995A Active JP7500555B2 (ja) 2018-10-25 2019-10-22 ヒト免疫不全ウイルス複製の阻害剤

Country Status (6)

Country Link
US (1) US20210393633A1 (cg-RX-API-DMAC7.html)
EP (1) EP3870575B1 (cg-RX-API-DMAC7.html)
JP (1) JP7500555B2 (cg-RX-API-DMAC7.html)
ES (1) ES2942998T3 (cg-RX-API-DMAC7.html)
PT (1) PT3870575T (cg-RX-API-DMAC7.html)
WO (1) WO2020084480A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
MA53973A (fr) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2020084491A1 (en) * 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
ES2969030T3 (es) * 2018-10-29 2024-05-16 Viiv Healthcare Uk No 5 Ltd Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana
US20220211704A1 (en) * 2019-04-30 2022-07-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
IL291436B1 (en) * 2019-09-20 2026-07-01 Ideaya Biosciences Inc History of indole and indazole sulfonamido 4-mutates as PARG inhibitors
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
WO2021070054A1 (en) * 2019-10-08 2021-04-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US12564595B2 (en) 2019-11-28 2026-03-03 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (zh) * 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
US9873680B2 (en) 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
LT3347352T (lt) 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
JP2022506399A (ja) * 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤

Similar Documents

Publication Publication Date Title
JP2022505841A5 (cg-RX-API-DMAC7.html)
JP2022505989A5 (cg-RX-API-DMAC7.html)
JP2022505637A5 (cg-RX-API-DMAC7.html)
JP2022500425A5 (cg-RX-API-DMAC7.html)
JP2022501370A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2022141835A5 (cg-RX-API-DMAC7.html)
JP2016527217A5 (cg-RX-API-DMAC7.html)
JP2012525393A5 (cg-RX-API-DMAC7.html)
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
RU2008152763A (ru) Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии
JP2005523922A5 (cg-RX-API-DMAC7.html)
RU2013121788A (ru) Ингибиторы репликации вич
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2022522694A5 (cg-RX-API-DMAC7.html)
JP2016510038A5 (cg-RX-API-DMAC7.html)
JP2006528700A5 (cg-RX-API-DMAC7.html)
JP2019500387A5 (cg-RX-API-DMAC7.html)
JP2020512337A5 (cg-RX-API-DMAC7.html)
JP2022525013A5 (cg-RX-API-DMAC7.html)
JP2017141277A5 (cg-RX-API-DMAC7.html)
JP2004517843A5 (cg-RX-API-DMAC7.html)
JP2019501879A5 (cg-RX-API-DMAC7.html)
JP2010505865A5 (cg-RX-API-DMAC7.html)
JP2022531251A5 (cg-RX-API-DMAC7.html)